Perrine Roux

Perrine Roux

Auto-generated profile, based on publicly available information

Perrine Roux

SESSTIM UMR 1252, Marseille, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
LKLaurent Karila
Laurent Karila
PRPerrine Roux
Perrine Roux
BRBenjamin Rolland
Benjamin Rolland
ABAmine Benyamina
Amine Benyamina
MRMichel Reynaud
Michel Reynaud
CLChristophe Lancon
Christophe Lancon
Cannabis remains the most commonly used and trafficked illicit drug in the world. Its use is largely concentrated among young people (15- to 34-year-olds). There is a variety of cannabis use patterns, ranging from experimental use to dependent use. Men are more likely than women to report both early initiation and frequent use of cannabis. Due to the high prevalence of cannabis use, the impact of cannabis on public health may be significant. A range of acute and chronic health problems associated with cannabis use has been identified. Cannabis can frequently have negative effects in its users, which may be amplified by certain demographic and/or psychosocial factors. Acute adverse effects include hyperemesis syndrome, impaired coordination and performance, anxiety, suicidal ideations/tendencies, and psychotic symptoms. Acute cannabis consumption is also associated with an increased risk of motor vehicle crashes, especially fatal collisions. Evidence indicates that frequent and prolonged use of cannabis can be detrimental to both mental and physical health. Chronic effects of cannabis use include mood disorders, exacerbation of psychotic disorders in vulnerable people, cannabis use disorders, withdrawal syndrome, neurocognitive impairments, cardiovascular and respiratory and other diseases.

16 October 2008 in Addiction
Verified
Journal Article
Closed access
PDF file
PRPerrine Roux
Perrine Roux
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
VVVirgine Villes
Virgine Villes
PDPierre Dellamonica
Pierre Dellamonica
IPIsabelle Poizot‐Martin
Isabelle Poizot‐Martin
BSBruno Spire
Bruno Spire

14 July 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CPCamelia Protopopescu
Camelia Protopopescu
FRFrançois Raffi
François Raffi
PRPerrine Roux
Perrine Roux
JRJacques Reynes
Jacques Reynes
PDPierre Dellamonica
Pierre Dellamonica
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
The aim of this study was to identify factors associated with non-adherence over a 10 year follow-up of the APROCO-COPILOTE cohort during the maintenance phase of highly active antiretroviral therapy (HAART). Overall, 1010 patients participated in this analysis, each having had at least 12 months of follow-up after HAART initiation and at least one self-reported adherence measure available during the follow-up period (month 12–month 120). Data collection was based on clinical records and self-administered questionnaires that gathered patients' psychosocial characteristics and experience with HIV disease and treatment. First, a generalized estimating equations (GEE) model was used to identify non-adherence predictors. Secondly, a Heckman two-stage approach was used in order to account for missing data bias and to measure the extent to which this could affect the results of the first model. Non-adherent behaviour was reported by 747 patients (2070 visits). After correcting for the bias due to missing data, non-adherence was independently associated with side effects, having a three times or more daily dosing regimen, experience of being at clinical stage B/C and being diagnosed as HIV-positive for <6 months. Non-adherence was more likely among patients who were younger, had children, were born in the European Union, had depressive symptoms, consumed alcohol daily and declared a lack of support from their main partner. Adjusting for missing outcome data changed the pattern of predictors. Reasons for non-adherence depended on both psychosocial conditions and treatment-related characteristics. To improve long-term patient outcomes for those at risk of adherence failure, tailor-made patient-specific psychosocial interventions and regimen-based strategies with improved tolerance need to be implemented.

1 November 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PRPerrine Roux
Perrine Roux
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
JCJulien Cohen
Julien Cohen
IRIsabelle Ravaux
Isabelle Ravaux
IPIsabelle Poizot‐Martin
Isabelle Poizot‐Martin
BSBruno Spire
Bruno Spire
Background.The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infecti

1 July 2012 in Journal of Addictive Diseases
Verified
Journal Article
Closed access
SSSharon Stancliff
Sharon Stancliff
HJHerman Joseph
Herman Joseph
CFChunki Fong
Chunki Fong
TFTerry Furst
Terry Furst
SCSandra D. Comer
Sandra D. Comer
PRPerrine Roux
Perrine Roux
The aim of this pilot study was to assess the effectiveness of buprenorphine/naloxone (BUP/NX) among marginalized, opioid-dependent individuals in terms of retention in and cycling into and out of a harm-reduction program. This pilot study enrolled 100 participants and followed them from November 2005 to July 2008. The overall proportion of patients retained in the program at the end of 3, 6, 9, and 12 months was 68%, 63%, 56%, and 42%, respectively. This pilot study demonstrated that BUP/NX could be successfully used to treat marginalized heroin users.

15 September 2016 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
DWDaniel Werb
Daniel Werb
RGRichard Garfein
Richard Garfein
TKThomas Kerr
Thomas Kerr
PDPeter Davidson
Peter Davidson
PRPerrine Roux
Perrine Roux
Steffanie StrathdeeSteffanie Strathdee
Steffanie Strathdee
Injection drug use remains a primary driver of HIV and HCV-related harms globally. However, there is a gap in efforts to prevent individuals from transitioning into injecting. People who inject drugs (PWID) play a key role in the transition of others into injecting, and while behavioral interventions have been developed to address this phenomenon, socio-structural approaches remain unexplored. To that end, we hypothesize that certain interventions designed to reduce injecting-related risk behaviors may also reduce the risk that PWID expose and introduce others into injecting. Identifying the preventive potential of existing interventions will inform broader efforts to prevent injecting and related harms. The Preventing Injecting by Modifying Existing Responses (PRIMER) study is a multi-country mixed methods study with an aim to investigate whether specific interventions (e.g., opioid substitution therapy, supervised injection facilities, stable housing, incarceration environments) and related factors (e.g., public injecting and gender) influence the likelihood that PWID initiate others into injecting. This study will (1) investigate the PWID participation in injection initiation; (2) identify factors influencing the risk that PWID expose others to or facilitate injection initiation; (3) describe drug scene roles that increase the risk of PWID facilitating injection initiation; and (4) evaluate the impact of structural, social, or biomedical interventions on the risk that PWID facilitate injection initiation. It does so by pooling observational data from cohort studies of PWID in six cities: Vancouver, Canada; San Diego, USA; Tijuana, Mexico; Paris, Marseille, and Bordeaux, France. Team members are conducting a prospective, multi-site study of PWID (n = 3050) in North America and France that includes quantitative and qualitative data collection through four separate cohort studies of PWID (San Diego, STAHR II; Tijuana, El Cuete IV; Vancouver, V-DUS; Bordeaux, Marseille, Paris and Strasbourg, COSINUS). PRIMER is the largest study of injection initiation to date and the first to investigate structural approaches to preventing injection drug use initiation. Findings have the potential to inform the development and scale up of new and existing interventions to prevent transitions into injecting. Preventing Injecting by Modifying Existing Responses (PRIMER), NIDA DP2-DA040256-01 .